Home/Filings/4/A/0001079973-06-000024
4/A//SEC Filing

Donnelly Richard G 4/A

Accession 0001079973-06-000024

CIK 0001167419other

Filed

Jan 16, 7:00 PM ET

Accepted

Jan 17, 11:19 AM ET

Size

13.9 KB

Accession

0001079973-06-000024

Insider Transaction Report

Form 4/AAmended
Period: 2005-12-23
Donnelly Richard G
DirectorPresident & CEO
Transactions
  • Award

    Options (Right to Buy)

    2005-12-23+100,000100,000 total
    Exercise: $0.96From: 2006-07-01Exp: 2015-12-23Common Stock (100,000 underlying)
  • Award

    Common Stock

    2005-12-23+75,000150,823 total
  • Purchase

    Common Stock

    2005-12-28$0.95/sh+5,000$4,750155,823 total
Holdings
  • Options (Right to Buy)

    Exercise: $0.60From: 2005-02-01Exp: 2015-02-01Common Stock (500,000 underlying)
    500,000
  • Warrants (Right to Buy)

    Exercise: $1.35From: 2005-05-06Exp: 2010-05-06Common Stock (28,571 underlying)
    28,571
Footnotes (5)
  • [F1]Pursuant to Board minutes dated December 23, 2005, the Company's Board of Directors awarded Mr. Donnelly 75,000 restricted shares of the Company's common stock. This stock award is exempt from Section 16(b) pursuant to Rule 16b-3d.
  • [F2]Mr. Donnelly purchased 5,000 shares of the Company's common stock on the open market for $0.95 per share. This transaction was reported on a Form 4 filed on January 9, 2006.
  • [F3]Options vest over three years, at the rate of 33.3% at the end of year one, 66.7% at the end of year two, and 100% at the end of year three.
  • [F4]Units purchased at a unit price of $0.875, with each unit consisting of one warrant and one share of common stock.
  • [F5]Pursuant to Board minutes dated December 23, 2005, the Company's Board of Directors granted Mr. Donnelly stock options to purchase 100,000 shares of the Company's common stock at $0.96 per share. The stock options vest on July 1, 2006, assuming that a cumulative minimum of $500,000 of sales of the new equine LH product is achieved by June 30, 2006. If such sales threshold is not achieved by June 30, 2006, the options shall lapse and expire. This stock option grant is exempt from Section 16(b) pursuant to Rule 16b-3d.

Issuer

AspenBio Pharma, Inc.

CIK 0001167419

Entity typeother

Related Parties

1
  • filerCIK 0001316244

Filing Metadata

Form type
4/A
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 11:19 AM ET
Size
13.9 KB